ZA200507395B - Process for the preparation of amorphous calcium salt of atorvastatin - Google Patents
Process for the preparation of amorphous calcium salt of atorvastatin Download PDFInfo
- Publication number
- ZA200507395B ZA200507395B ZA200507395A ZA200507395A ZA200507395B ZA 200507395 B ZA200507395 B ZA 200507395B ZA 200507395 A ZA200507395 A ZA 200507395A ZA 200507395 A ZA200507395 A ZA 200507395A ZA 200507395 B ZA200507395 B ZA 200507395B
- Authority
- ZA
- South Africa
- Prior art keywords
- preparation
- atorvastatin calcium
- solvent
- amorphous atorvastatin
- amorphous
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 58
- 238000002360 preparation method Methods 0.000 title claims description 44
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title claims description 30
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title claims description 30
- 229960005370 atorvastatin Drugs 0.000 title claims description 30
- 159000000007 calcium salts Chemical class 0.000 title claims description 14
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 claims description 83
- 229960001770 atorvastatin calcium Drugs 0.000 claims description 74
- 239000002904 solvent Substances 0.000 claims description 52
- 239000000243 solution Substances 0.000 claims description 44
- 239000003960 organic solvent Substances 0.000 claims description 32
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 31
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 27
- 239000011541 reaction mixture Substances 0.000 claims description 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 25
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 14
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 11
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 11
- QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 claims description 10
- 239000001639 calcium acetate Substances 0.000 claims description 10
- 235000011092 calcium acetate Nutrition 0.000 claims description 10
- 229960005147 calcium acetate Drugs 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 238000002955 isolation Methods 0.000 claims description 10
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 9
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000011575 calcium Substances 0.000 claims description 8
- 229910001424 calcium ion Inorganic materials 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims description 8
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 7
- 239000001110 calcium chloride Substances 0.000 claims description 7
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 7
- 159000000000 sodium salts Chemical class 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000007935 neutral effect Effects 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 2
- 200000000007 Arterial disease Diseases 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 208000020084 Bone disease Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 201000010374 Down Syndrome Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 206010044688 Trisomy 21 Diseases 0.000 claims description 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 230000017531 blood circulation Effects 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000001033 ether group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- VVRPOCPLIUDBSA-CNZCJKERSA-M sodium;(3r,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate Chemical class [Na+].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 VVRPOCPLIUDBSA-CNZCJKERSA-M 0.000 claims 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- 239000002244 precipitate Substances 0.000 description 16
- 238000003756 stirring Methods 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- 239000012141 concentrate Substances 0.000 description 10
- 235000008504 concentrate Nutrition 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 9
- -1 trichioroethane Chemical compound 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 239000013543 active substance Substances 0.000 description 8
- 239000013078 crystal Substances 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 4
- 239000000920 calcium hydroxide Substances 0.000 description 4
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 4
- 229960004132 diethyl ether Drugs 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000003245 coal Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 239000011877 solvent mixture Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 1
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000005280 amorphization Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
1 $a to WO 2004/089895 PCT/S12004/000019
Lek Pharmaceuticals d.d.
Process for the preparation of amorphous calcium salt of atorvastatin
Present invention relates to the field of organic synthesis, more exactly, it relates to the manufacturing process for preparing pharmaceutically acceptable salt of atorvastatin in amorphous form. In a technologically simple way, the invention enables the preparation of amorphous atorvastatin calcium without intermediate isolation of solid crystalline atorvastatin calcium.
Prior Art
Atorvastatin calcium, a substance with chemical name of hemicalcium salt (R-(R*,R*))-2-(4-fluorophenyl)-B,3-dihydroxy-5-(1-methylethyl)-3-phenyl- 4((phenylamino)carbonyl)-1H-pyrol-1-heptanoic acid and with the chemical formula
F
OH OH ©O DD a ENN NC
NH g eo 2 is known as inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-
CoA reductase), that is an enzyme catalyzing the intracellular synthesis of cholesterol. Thus the HMG-CoA reductase inhibitors are especially applicable at treating hypercholesterolemia and hyperlipidemia.
‘«,
The substance atorvastatin was first described in U.S. Patent 4,681,893 with a generic formula, its salt atorvastatin calcium, however, having been first disclosed in
U.S. Patent 5,273,995. Processes for preparing atorvastatin, salts thereof and key intermediates have been described in several patent applications, such as international publications WO 89/07598, WO 92/06868, WO 93/07115, WO 04/20492. As active pharmaceutical substance atorvastatin, usually in the form of a calcium salt, is present in the pharmaceutical form, such as tablets, capsules, powders, and other forms of oral application of medicament.
Atorvastatin calcium may exist in different crystal forms described in different patent applications, such as international publications WO 97/03958, WO 97/03959, WO 01/36384, WO 02/41834, WO 02/43732, WO 02/51804, WO 02/57229, WO 03/004470. The great number of known crystal forms of atorvastatin calcium indicates the fact that the substance is more or less stable in several polymorphous forms.
It is known that atorvastatin calcium obtained by different manufacturing processes is precipitated as low crystalline solid substance having a poorly defined structure. A consequence thereof are relatively badly repeatable processes for preparing the final substances with regard to the polymorphous form, i.e., pharmaceutical active substances prepared in this way are not suitable to be incorporated into pharmaceutical forms, which require strict repeatability in regard to the polymorphous form of active substance.
Processes of preparing amorphous atorvastatin calcium have been disclosed in different patent applications, such as WO 97/03960, WO 00/71116, WO 01/28999,
WO 01/42209, WO 02/057228, WO 03/018547. These processes proceed over previously isolated crystal atorvastatin calcium, or an undefined mixture of crystal and amorphous atorvastatin calcium. Isolation of substance in crystalline or non- crystalline form and further amorphization represent a two-step synthesis process, which lowers the yield process as a whole.
i. WO 2004/089895 PCT/S12004/000019
Processes of preparing non-crystal atorvastatin calcium without intermediate isolation of solid product have been disclosed in international applications WO 01/72706, WO 02/059087, WO 02/083638 and WO 02/083637. Said amorphous forms are not entirely amorphous, these being structures with crystallization nuclei, which in different references are characterized as amorphous. In international patent application WO 03/018547 there is disclosed a process for preparing amorphous atorvastatin calcium with aqueous alkaline or earth alkaline metal bases with advantageous use of calcium hydroxide.
It is known that the amorphous form of an individual pharmaceutical active substance has different dissolution characteristics and a different bioavailability in comparison to crystalline forms (Konno T., Chem. Pharm. Bull., 1990, 38:2003- 2007). For some therapeutical indications, bioavailability is one of the key parameters at determining the forms of the pharmaceutical active substance entering the pharmaceutical form. It is generally known that pharmaceutical active substances in amorphous form are better soluble, or dissolve more quickly than crystalline ones. An advantage of amorphous pharmaceutical active substance over crystalline one is especially distinct at poorly soluble substances, such as, e.g., atorvastatin calcium, which is expressed in a higher biological applicability of the active substance.
Short Description of the Drawings
Fig. 1 shows an X-ray powder diffractogram of atorvastatin calcium sait obtained by the process according to Example 1.
Fig. 2 shows an X-ray powder diffractogram of atorvastatin calcium salt obtained by the process according to Example 2.
Fig. 3 shows an X-ray powder diffractogram of atorvastatin calcium obtained by the process according to the preparation Example 3.
.
N WO 2004/089895 PCT/S12004/000019
Fig. 4 shows an X-ray powder diffractogram of atorvastatin calcium obtained by the process according to Example 4.
Fig. 8 shows an X-ray powder diffractogram of atorvastatin calcium obtained by the process according to Example 5.
Description of the Invention with Examples in view of above-mentioned advantages of amorphous atorvastatin, such as better bioavailability and better solubility, there is present a constant need to prepare amorphous atorvastatin calcium in one step without isolation of the intermediate solid product, which essentially contributes to lowering the production cost. We have ascertained that the key factor in this process is the selection of the organic solvent used in the step of forming calcium salt of atorvastatin, i.e., prior to precipitation thereof. We found out that atorvastatin calcium is very well soluble in mixture of chlorinated organic solvents selected from the group consisting of chloroform, dichloromethane, trichioroethane, or tetrachloroethane and a non-hydroxylic organic solvent, such as e.g., tetrahydrofuran and water. Additionally surprisingly we have found that atorvastatin calcium in spite of its ionic nature is well soluble in a mixture of cyclic hydrocarbon solvent selected from the group consisting of cyclohexane, cyclopentane or methyl cyclohexane and non-hydroxylic organic solvent, such as, e.g., tetrahydrofuran, and water.
Especially advantageous is the fact that in said mixture of solvents the substance is better soluble than in a water solution. Consequently, in the step of preparing calcium salt of atorvastatin with the aid of an inorganic source of calcium ions, a systems of solvents may be used — a chlorinated organic solvent/an organic non- hydroxylic solvent/water or a cyclic hydrocarbon solvent/an organic non-hydroxylic solvent/water, without precipitation having taken place of less soluble compounds, such as calcium inorganic salts and sodium salt of atorvastatin, which ensures from alkalization of the reaction mixture with sodium hydroxide.
~ WO 2004/089895 PCT/S12004/000019
The main object of the present invention is, consequently, to prepare an amorphous form of atorvastatin calcium without intermediate isolation or precipitation, respectively, of crystailine or undefined mixture of crystalline and amorphous atorvastatin calcium. This object is attained in that the formation of atorvastatin calcium salt is carried out in solvent mixtures, namely, solvent mixture of chlorinated organic solvent and an organic non-hydroxylic solvent and water or solvent mixture of cyclic hydrocarbon solvent and an organic non-hydroxylic solvent and water.
In the step of formation of calcium salt of atorvastatin no precipitation of calcium or any other salt of atorvastatin takes place. Chlorinated organic solvents or cyclic hydrocarbon solvents may be used in quantities which in a mixture with an organic non-hydroxylic solvent and water ensure total solubility of all components until the last synthesis step when atorvastatin calcium salt precipitates from the solution with an addition of solvent in which the product is low soluble, or is insoluble, respectively.
Different calcium sources may be used for the preparation of calcium salt of atorvastatin, as for example water solution of calcium acetate or calcium chloride, respectively. The present invention can use calcium acetate or calcium chloride.
Namely, by using some of other calcium sources, such as, e.g., calcium hydroxide, it is necessary before the precipitation of atorvastatin from the organic solvents mixture to filtrate the mixture due to the circumstance that calcium hydroxide is less soluble in chlorinated organic solvents in comparison to calcium acetate. An additional disadvantage of presence of calcium hydroxide in the reaction mixture with the chlorinated organic solvent or cyclic hydrocarbon solvents is in the appearance of reaction mixture turbidity, which effects on the forming of the desired amorphous atorvastatin and the amount of impurities present in the final product, as well. In this case the product should, for use in a pharmaceutical formulation, be additionally purified.
A further object of the present invention is the preparation of amorphous form of atorvastatin calcium according to the process, which includes the following steps:
a) Preparation of a neutral reaction mixture containing sodium salt of atorvastatin, which is dissolved in a mixture of non-hydroxylic organic solvent, such as, e.g., tetrahydrofuran, and water in an 8:1 ratio. The obtained reaction mixture shows a pH in the range between 6.5 and 8.0. b) To the obtained solution there is added a onefold to a fivefold volume with respect to the existing volume of chlorinated organic solvent selected from the group consisting of dichloromethane, tetrachloroethane, trichioroethane, chloroform, preferably chloroform or cyclic hydrocarbon solvent selected from the group consisting of cyclohexane, cyclopentane or methyl cyclohexane, preferably cyclohexane, and 0.5fold to a twofold volume of saturated water solution of sodium chloride with respect to the existing volume. Optionally in case chlorinated organic solvents are used and necessary in case cyclic hydrocarbon solvents are used, both organic and water layer are separated in a funnel separator. After the separation the organic layer is saved for further use in the preparation process. c) To the reaction mixture of previously prepared sodium salt of atorvastatin an equivalent or an excess quantity of calcium ions source is added. As source of calcium ions, water solution of calcium acetate or calcium chloride, preferably calcium acetate is used. The product atorvastatin calcium salt is formed in the solution. d) Isolation of atorvastatin calcium salt proceeds according to hitherto known and disclosed processes.
An object of the present invention is also the preparation of amorphous form of atorvastatin calcium from the compound of formula | or Il without intermediate isolation of crystal or undefined mixture of crystal and amorphous atorvastatin calcium. An advantage of this process is that it assures a pharmaceutical quality of the final product without special additional purification of the obtained substance.
© WO 2004/089895 PCT/S12004/000019
According to the process, which is object of present invention, the compound with the formula | or Il
F F
Ri Re
CI2 kL Ney. 7 EN NG 2 N o
NH ( I = I
QQ ently repre of o ie carbon atoms, phenyl, or Ry in R2 are taken together as (-CHz)y-, wherein n may be 4 or 5; Ry may represent straight or branched chain alkyl of from one to eight carbon atoms or cycloalkyl of from three to six carbon atoms, R3 may represent tert-butyl, tert-amyl or a,a-dimethylbenzyi.
Group -O-R3 may be substituted by the group with the formula:
Ry —nN/
Rg wherein R; and Rs may independently represent - alkyl with one to ten carbon atoms, - cyclopropyl, - cyclobutyl, -cyclopentyl, - cyclohexyl, - benzyl or phenyl, or Rs in Rs are taken together to form: -(CHz)s-, -(CH2)s-, -(CH(R®)-CHz)z-, -(CH(R®)-CH2)s, -(CH(R®)-(CH2)2-CH(R®))-, ~(CH(R®}-(CH2)s-CH(R®))-, -CH2-CH2-O-CH2-CH>-,
-CH(R®)-CH,-0-CHy-CHa-, -CH(R®)-CH,-0-CH,-CH,(R®)-, wherein R® represents alkyl with one to four carbon atoms, is dissolved in a non-hydroxylic solvent, such as, e.g., tetrahydrofuran.
The obtained solution is acidified and stirred at a temperature between 5 and 40 °C, preferably at room temperature until it is by thinlayer chromatography no longer possible to detect the starting compounds with the formula | or Il. Subsequently, to the solution a base such as, e.g., NaOH is added, until the pH of the solution does not reach a value between 8.0 and 14.0, preferably between 9.0 and 12.0. The obtained solution is mixed at temperature between 5 and 40 °C, preferably at room temperature. To the reaction mixture, under intense stirring, an acid is cautiously added until the pH is not in the range between 6.5 and 8.0, preferably 7.8. The formed reaction mixture contains sodium salt of atorvastatin.
To the obtained solution there is added with respect to its existing volume a onefold to a fivefold volume of chlorinated organic solvent selected from the group consisting of dichloromethane, trichloroethane, tetrachloroethane, chloroform, preferably chloroform or cyclic hydrocarbon solvent selected from the group consisting of cyclohexane, cyclopentane, and methyl cyclohexane, and a 0.5fold to a twofold volume of saturated aqueous solution of sodium chloride with respect to the existing volume. If the cyclic hydrocarbon solvent is used the resulted layers are separated in a funnel separator. The organic layer is saved for further reaction process.
To the reaction mixture or to the organic layer from the separation process an equivalent quantity of calcium ions or excess thereof is added. As source of calcium ions, aqueous solution of calcium acetate or calcium chloride, preferably calcium acetate, is used. To the organic phase of the obtained two-phase system a drying agent, such as, e.g., magnesium sulphate, is added, which is later on removed by filtration. The reaction mixture is further on concentrated to a threshold value when
= WO 2004/089895 PCT/S12004/000019 the concentrate is still entirely clear, and during this process, however, the solution must always be entirely clear.
Optionally afterwards the reaction mixture is concentrated to about half of initial volume or a threshold value when the concentrate is still entirely clear, during this process, however, the solution must always be entirely clear. After that twofold of concentrated mixture volume is added a solvent in which atorvastatin is well soluble, i.e., e.g., methanol, ethanol or propanol, and which mixes with used chlorinated organic solvent or cyclic hydrocarbon and a portion of an active coal is also added to the said concentrated mixture. Reaction mixture is mixed for about one hour and filtered. The reaction mixture is further concentrated to a threshold value when the concentrate is still entirely clear, during this process, however, the solution must always be entirely clear.
To the obtained concentrate optionally a twofold up to a sixfold, preferably a threefold, volume of solvent is added to its existing volume, The solvent is such that in which atorvastatin is well soluble, i.e., e.g., methanol, ethanol or propanol, and which is capable of mixing with used chlorinated organic solvent or cyclic hydrocarbon solvent according to the present invention and as well with the solvent used in the next step for precipitating atorvastatin calcium. The reaction mixture is then concentrated to a threshold when the concentrate is still entirely clear, and during this process, however, the solution must always be entirely clear.
Subsequently, a 0.4fold to a 0.8fold volume of solvent with regard to the existing volume of solution, preferably a 0.4fold volume of solvent, in which atorvastatin calcium is not soluble, or is low soluble, is optionally added. As solvent, ether, preferably diisopropyl ether, may be used. The reaction mixture prepared in such a way is under intense stirring poured into a fourfold to eightfold volume of the same solvent with regard to the existing volume, preferably fivefold volume of the same solvent. The reaction mixture is stirred at a temperature from 10 to 30 °C, preferably at room temperature. In this step a precipitate of final product - amorphous atorvastatin calcium salt is formed. After removing the solvent by filtration, optionally digerating the product with the organic solvent in which atorvastatin calcium salt is
= WO 2004/089895 PCT/S12004/000019 not soluble or is low soluble and washing the product on the filter, final product amorphous atorvastatin calcium salt is dried in vacuum at a temperature from 35 to 45 °C.
A further object of the present invention is a pharmaceutical composition and form containing amorphous atorvastatin calcium obtained according to the present invention, and pharmaceutically acceptable additives. An advantage of atorvastatin calcium obtained according to the present invention lies in that prior to application in pharmaceutical industry, the active substance need not be additionally purified. The pharmaceutical form may cover tablets, capsules, powders, bags, syrups or suspensions for oral, parenteral, rectal, transdermal or nasal application. The pharmaceutical form may be prepared according to conventional processes known in prior art.
Amorphous atorvastatin calcium prepared according to the present invention is used for preparing medicaments for the treatment of diseases selected from the group consisting of dislipidemia, hyperlipidemia, hypercholesterolemia, aterosclerosis, arteriosclerosis, cardiovascular diseases, coronary arterial diseases, coronary heart diseases, disorders of blood circulation, inflammation diseases, bone diseases, disorders of processing beta amyloid precursor protein, such as Alzheimer's disease or Down's syndrome.
The present invention is illustrated by the following examples. Although these examples are illustrative, they are not intended to be limiting.
Example 1. 4.37 g tert-butyl (6-{2-[2-(4-fluorophenyl)-5-isopropyl-3-phenyi-4- phenylcarbamoylpyrol-1-yf]-ethyl}-2,2-dimethyl-[1 ,3]dioxan-4-yl)-acetate are dissolved in 35 ml tetrahydrofuran, then 5 ml 10 % hydrochloric acid are added, and the solution is stirred at room temperature for 15 hours. 1.2 g solid sodium hydroxide is added, and it is stirred for further 3 hours. pH of the reaction mixture is set to 7.8 with 5N hydrochloric acid at room temperature. To the obtained solution, 50 ml chloroform and 25 ml saturated solution of sodium chloride are added.
To this solution under intense stirring is added a solution of 0.76 g Ca(OAc)2.H20 in ml water. The obtained two-phase system is stirred for 30 minutes at 30 °C, and the layers are separated. The organic phase is dried with magnesium sulphate and concentrated. To the clear concentrate, methanol is added, and the mixture is once again concentrated.
To the clear concentrate, 5 mi diisopropylether are added. The obtained solution is under intense stirring added into 100 ml diisopropylether. It is stirred for 1 hour and fitrated, after that precipitate is digerated with 50 mi ether, filtrated and the precipitate is on the filter washed with three times 10 ml ether each. The precipitation is dried in vacuum of about 1 mbar at 45 °C overnight.
Obtained are 3.74 g amorphous calcium salt of atorvastatin.
Example 2. 4.37 g tert-butyl (6-{2-[2-(4-fluorophenyl)-56-isopropyl-3-phenyl-4- phenylcarbamoylpyrol-1 -yl}-ethyl}-2,2-dimethyl-[1,3]dioxan-4-yi}-acetate are dissolved in 35 ml tetrahydrofuran, then 5 mi 10 % hydrochloric acid are added and the solution is stirred at room temperature for 15 hours. 1.2 g solid sodium hydroxide is added, and it is stirred for further 3 hours. pH of the reaction mixture is set to 7.8 with 5N hydrochloric acid at room temperature. To the obtained solution, 100 ml dichloromethane and 25 ml saturated solution of sodium chloride are added.
To this solution there is under intense stirring added a solution of 0.76 g
Ca(OAc),.H20 in 10 ml water. The obtained two-phase system is stirred for 1 hour at 30 °C, and the layers are separated. The organic phase is dried with magnesium sulphate and concentrated.
To the clear concentrate, 5 ml diisopropylether are added. The obtained solution is under intense stirring added into 100 mi diisopropylether. lt is stirred for 1 hour and filtrated, after that precipitate is digerated with 50 mi ether, filtrated and the precipitate is on the filter washed with three times 10 mi ether each. The precipitate is dried in vacuum of about 1 mbar at 45 °C overnight.
Obtained are 3.09 g amorphous calcium salt of atorvastatin.
Example 3. 4.37 g tert-butyl (6-{2-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- phenylcarbamoylpyrol-1-yll-ethyl}-2,2-dimethyl-[1,3]dioxan-4-yl)-acetate are dissolved in 35 ml tetrahydrofuran, then 5 ml 10 % hydrochloric acid are added, and the solution is stirred at room temperature for 15 hours. 1.2 g solid sodium hydroxide is added, and it is stirred for further 3 hours. pH of the reaction mixture is set to 7.8 with 5N of hydrochloric acid at room temperature. To the obtained solution, 50 ml chloroform and 25 ml saturated solution of sodium chloride are added.
To this solution there is under intense stirring added a solution of 0.632 g¢
CaCl,.2H20 in 10 mi water. The obtained two-phase system is stirred for 30 minutes at 30 °C, and the layers are separated. The organic phase is dried with magnesium sulphate and concentrated.
To the clear concentrate, 5 ml diisopropylether are added. The obtained solution is under intense stirring added into 100 ml diisopropylether. It is stirred for 1 hour and filtrated, after that precipitate is digerated with 50 ml ether, filtered and the separated precipitate is on the filter washed with three times 10 ml ether each. The precipitate is dried in vacuum of about 1 mbar at 45 °C overnight.
Obtained are 3.65 g amorphous calcium salt of atorvastatin.
Example 4.
8.74 ag tert-butyl (6-{2-[2-(4-fluorophenyl)-5-isopropyl-3-phenyi-4- phenylcarbamoylpyrol-1-yl-ethyl}-2,2-dimethyl-[1,3]dioxan-4-yi)-acetate are dissolved in 70 ml tetrahydrofuran, then 10 ml 10 % hydrochloric acid are added and the solution is stirred at room temperature for 15 hours. 2.4 g solid sodium hydroxide are added, and it is stirred for further 3 hours. pH of the reaction mixture is set to 7.8 with 5N hydrochloric acid at room temperature. To the obtained solution, 70 mi cyclohexane and 30 ml saturated water solution of sodium chloride are added. The layers are separated.
To the organic phase, under intensive stirring, a solution of 1.52 g Ca(OAc),.H20 on ml water is added. The obtained two-phase system is stirred for 1 hour at 30 °C, and the layers are separated. The organic phase is dried with MgSO, MgSO, is filtered off and the mixture is vaporized to a volume of about 60 mi.
The obtained solution is under intensive stirring added into 200 ml diisopropyt ether.
It is stirred for 1 hour and filtrated, precipitate is digerated with 100 ml diethyl ether, filtrated and the precipitate is on the filter washed with three times 20 ml diethyl ether each. The precipitate is dried in a vacuum about 1 mbar at 45 °C overnight.
Obtained are 7.08 g amorphous calcium salt of atorvastatin.
Example 5. 8.47 g tert-butyl (6-{2-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- phenylcarbamoylpyrol-1-yl}-ethyl}-2,2-dimethyl-[1,3]dioxan-4-yi)-acetate are dissolved in 70 mi tetrahydrofuran, then 10 ml 10 % hydrochloric acid are added, and the solution is stirred at room temperature for 15 hours. 2.4 g solid sodium hydroxide are added, and it is stirred for further 3 hours. pH of the reaction mixture is set to 7.8 with 5N hydrochloric acid at room temperature. To the obtained solution, 70 ml cyclohexane, and 30 mi saturated water solution of sodium chloride are added. The layers are separated.
To the upper layer is under intense stirring added a solution of 1.52 g Ca(OAc). HO in 20 ml water. The obtained two-phase system is stirred for 1 hour at 30 °C, and the layers are separated.
The organic phase is dried with MgSO,, MgSO is filtrated off and the residue is evaporated to a volume about 50 ml, then 100 mi methano! and 0.874 g of active coal is added. The mixture is stirred for 1 hour, and active coal filtrated off. The mixture is concentrated to a volume of about 20 ml.
To the clear concentrate, 10 ml diisopropylether are added. The obtained solution is under intense stirring added into 200 ml diisopropylether. lt is stirred for 1 hour and filtrated, then precipitate is digerated with 100 mi diethyl ether, filtered and the precipitate is on the filter washed with three times 20 mi diethylether each. The precipitate is dried in vacuum of about 1 mbar at 45 °C overnight.
Obtained are 5.83 g amorphous calcium salt of atorvastatin.
The obtained samples of amorphous atorvastatin calcium salt were analyzed with X- ray powder diphraction analysis, and exhibit X-ray powder diffractograms shown in
Figs. 1to 5.
The X-ray powder diffraction pattern was collected on a Philips PW1710 diffractometer in reflection geometry. The instrument was regularly calibrated with silicon standard. A standard Philips back-loading sample holder was used. Sample storage, mounting, and data collection were performed at room temperature.
Instrumental parameters were: CuK, radiation (30 mA, 40 kV, A = 1.5406 A, variable divergence slit (approx. 12 x 16 mm irradiated area), 0.4 mm receiving slit, graphite monochromator on the secondary side, scintillation counter. Data collection parameters were: 26 range from 4 ° to 37 °, step scan mode in steps of 0.04 © 28, integration time 1 second at each step.
Claims (33)
1. A process for the preparation of amorphous atorvastatin calcium, which comprises preparation of calcium salt of atorvastatin in a mixture of solvents consisting of a chlorinated organic solvent, a non-hydroxylic organic solvent, and water and at which the source of calcium ions is selected from the group consisting of calcium acetate and calcium chloride.
2. A process for the preparation of amorphous atorvastatin calcium, which comprises preparation of calcium salt of atorvastatin in a mixture of solvents consisting of a cyclic hydrocarbon solvent, a non-hydroxylic organic solvent, and water and at which the source of calcium ions is selected from the group consisting of calcium acetate and calcium chloride.
3. A process for the preparation of amorphous atorvastatin calcium according to claim 1, characterized in that the chlorinated organic solvent is selected from the group consisting of chloroform, trichloroethane, dichloromethane and tetrachloroethane.
4. A process for the preparation of amorphous atorvastatin calcium according to claim 3, characterized in that the chlorinated organic solvent is chloroform.
5. A process for the preparation of amorphous atorvastatin calcium according to claim 3, characterized in that the chlorinated organic solvent is dichloromethane.
6. A process for the preparation of amorphous atorvastatin calcium according to claim 2, characterized in that the cyclic hydrocarbon solvent is selected from the group consisting of cyclohexane, cyclopentane and methyl cyclohexane.
7. A process for the preparation of amorphous atorvastatin calcium according to claim 6, characterized in that the cyclic hydrocarbon solvent is cyclohexane.
8. A process for the preparation of amorphous atorvastatin calcium according to claim 6, characterized in that the cyclic hydrocarbon solvent is cyclopentane.
9. A process for the preparation of amorphous atorvastatin calcium according to claim 6, characterized in that the cyclic hydrocarbon solvent is methyl cyclohexane.
10. A process for the preparation of amorphous atorvastatin calcium according to claims 1 and 2, characterized in that the non-hydroxylic organic solvent is tetrahydrofuran.
11. A process for the preparation of amorphous atorvastatin calcium which comprises: a) preparation of a neutral reaction mixture containing sodium salt of atorvastatin, b) addition of chlorinated organic solvent selected from the group consisting of dichloromethane, trichloroethane, tetrachloroethane and chloroform, or addition of cyclic hydrocarbon solvent selected from the group consisting of cyclohexane, cyclopentane, and methyl cyclohexane, c) addition of an equivalent or an excess quantity of calcium ions source selected from the group consisting of calcium acetate and calcium chloride, d) isolation of atorvastatin calcium.
12. A process for the preparation of amorphous atorvastatin calcium according to claim 11 characterized in that the neutral reaction mixture comprising atorvastatin sodium salt is prepared by a process which comprises: a) dissolving a compound of formula | or il F F Y RR >< ° ® >< oO 0 AIX K XR ZN 0 2 N o NH I = of of A wherein R; and R; may independently represent hydrogen, alkyl with one to three carbon atoms, phenyl, or Ry in R; are taken together as (-CHz).-, wherein n may be 4 or 5; R® may represent straight or branched chain alkyl of from one to eight carbon atoms or cycloalkyl of from three fo six carbon atoms group -O-R; may be substituted by the group with the formula: Ra —N_ Rg wherein R; and Rs may independently represent alkyl with one to ten carbon atoms, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, benzyl or phenyl, or Rs in Rs are taken together to form: -(CHz)s-, -(CHz)s-, -(CH(R®)-CHa)s-, «(CH(R®)-CH2)s-, - (CH(R®)(CH2)CH(R®)-, -(CH(R®)-(CH,)s-CH(R®))-, -CH,-CHz-O-CHz-CHz-, - CH(R®)-CH2-O-CHp-CHz-, -CH(R®)-CH,-O-CH2-CH,(R®)-, wherein R® represents alkyl with one to four carbon atoms, in a non-hydroxylic organic solvent b) preparing sodium salt of atorvastatin in a neutral reaction mixture,
13. A process for the preparation of amorphous atorvastatin calcium according to claim 12, characterized in that a non-hydroxylic organic solvent is tetrahydrofuran.
14. A process for the preparation of amorphous atorvastatin calcium according to claim 11, characterized in that the neutral reaction mixture comprising sodium salt of atorvastatin shows a pH between 6.5 and 8.0.
15. A process for the preparation of amorphous atorvastatin calcium according to claim 11, characterized in that the chlorinated organic solvent is selected from the group consisting of chloroform, trichloroethane, dichloromethane, and tetrachioroethane.
16. A process for the preparation of amorphous atorvastatin calcium according to claim 15, characterized in that the chlorinated organic solvent is chloroform.
17. A process for the preparation of amorphous atorvastatin calcium according to claim 15, characterized in that the chlorinated organic solvent is dichloromethane.
18. A process for the preparation of amorphous atorvastatin calcium according to claim 11, characterized in that the cyclic hydrocarbon solvent is selected from the group consisting of cyclohexane, cyclopentane and methyl cyclohexane.
19. A process for the preparation of amorphous atorvastatin calcium according to claim 18, characterized in that the cyclic hydrocarbon solvent is cyclohexane.
20. A process for the preparation of amorphous atorvastatin calcium according to claim 18, characterized in that the cyclic hydrocarbon solvent is cyclopentane.
21. A process for the preparation of amorphous atorvastatin calcium according to claim 18, characterized in that the cyclic hydrocarbon solvent is methyl cyclohexane.
22. A process for the preparation of amorphous atorvastatin calcium according to claims 11, characterized in that the chlorinated organic solvent or cyclic hydrocarbon solvent is added in a onefold to fivefold quantity with respect to the existing volume of the solution.
23. A process for the preparation of amorphous atorvastatin calcium according to claims 11, characterized in that simultaneously with an addition of the chlorinated organic solvent or cyclic hydrocarbon solvent also a 0.5fold to a twofold quantity of saturated aqueous solution of sodium chloride with respect to the existing volume of the solution is added.
24. A process for the preparation of amorphous atorvastatin calcium according to claim 11, characterized in that the isolation of atorvastatin calcium comprises an addition of solvent in which atorvastatin calcium is poorly soluble.
25. A process for the preparation of amorphous atorvastatin calcium according to claim 24, characterized in that the solvent in which atorvastatin calcium is poorly soluble, is ether.
26. A process for the preparation of amorphous atorvastatin calcium according to claim 25, characterized in that the solvent in which atorvastatin calcium is poorly soluble, is diisopropylether.
27. A process for the preparation of amorphous atorvastatin calcium according to claim 11, characterized in that the isolation of atorvastatin calcium comprises: a) adding a solvent in which atorvastatin calcium is well soluble, b) concentrating the obtained mixture, c¢) adding a solvent in which atorvastatin calcium is poorly soluble so that it, consequently, separates from the reaction mixture.
28. A process for the preparation of amorphous atorvastatin calcium according to claim 27, characterized in that the solvent in which atorvastatin calcium is well soluble is selected from the group consisting of methanol, ethanol and propanol.
29. A process for the preparation of amorphous atorvastatin calcium according to claim 28, characterized in that the solvent in which atorvastatin calcium is well soluble is methanol.
30. A process for the preparation of amorphous atorvastatin calcium according to claim 27, characterized in that the solvent in which atorvastatin calcium is poorly soluble is ether.
31. A process for the preparation of amorphous atorvastatin calcium according to claim 30, characterized in that the solvent in which atorvastatin calcium is poorly soluble is diisopropylether.
32. Use of amorphous atorvastin calcium, prepared by the process as described in any previous claims from 1 to 31 for the preparation of a medicament for the treatment of diseases selected from the group consisting of dislipidemia, hyperlipidemia, hypercholesterolemia, aterosclerosis, arteriosclerosis, cardiovascular diseases, coronary arterial diseases, coronary heart diseases, disorders of blood circulation, inflammation diseases, bone diseases, disorders of processing beta amyloid precursor protein, such as Alzheimer's disease or Down's syndrome.
33. A pharmaceutical form comprising amorphous atorvastatin calcium prepared by the process as described in any previous claims from 1 to 32, and pharmaceutically acceptable ingredients.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SI200300100A SI21461A (en) | 2003-04-11 | 2003-04-11 | Preparation of amorphous calcium salt of atorvastatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200507395B true ZA200507395B (en) | 2007-02-28 |
Family
ID=33308853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200507395A ZA200507395B (en) | 2003-04-11 | 2005-09-14 | Process for the preparation of amorphous calcium salt of atorvastatin |
Country Status (2)
| Country | Link |
|---|---|
| SI (1) | SI21461A (en) |
| ZA (1) | ZA200507395B (en) |
-
2003
- 2003-04-11 SI SI200300100A patent/SI21461A/en not_active IP Right Cessation
-
2005
- 2005-09-14 ZA ZA200507395A patent/ZA200507395B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI21461A (en) | 2004-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8697741B2 (en) | Process for the preparation of amorphous calcium salt of atorvastatin | |
| RU2247113C2 (en) | Method of preparing amorphous atorvastatine | |
| CA2450111C (en) | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) | |
| JP5412484B2 (en) | Salt form of atorvastatin | |
| CN1487921A (en) | Preparation of non-crystalline at orvastatin calcium | |
| JP2007505090A (en) | Bis [(E) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5-yl] (3R, 5S) -3,5-dihydroxy- 6-Heptenoic acid] calcium salt crystal form | |
| EA008441B1 (en) | CRYSTALLINE [R-(R,R)]-2(4-FLUOROPHENYL)- β δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL -4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-HEPTANOIC ACID CALCIUM SALT (2:1) | |
| RU2315755C2 (en) | Crystalline forms of [r[(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrol-1-heptanoic acid | |
| ZA200507395B (en) | Process for the preparation of amorphous calcium salt of atorvastatin | |
| US20080262074A1 (en) | Salt Forms of [R-(R*,R*)]-2-(4-Fluorophenyl)-Beta,Delta-Dihydroxy-5-(1-Methylethyl)-3-(Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid | |
| EP2483248B1 (en) | Crystalline form i rosuvastatin zinc salt | |
| US8071638B2 (en) | Solid states of atorvastatin potassium | |
| CA2521833C (en) | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) | |
| EP1786771A1 (en) | Novel polymorphs of the potassium salt of atorvastatin | |
| SI21505A (en) | Preparation of amorphous calcium salt of atorvastatin | |
| CN103328450A (en) | Crystalline pharmaceutically active ingredients |